Avastin Data, Policy Implications Warrant Hearing On Breast Cancer Use, Genentech Tells FDA
Executive Summary
Genentech has come out fighting on multiple fronts in its attempt to retain Avastin’s breast cancer indication, proposing a new confirmatory study, submitting new Phase IV data and attacking FDA’s interpretation of both the underlying scientific data and its regulations on withdrawal.
You may also be interested in...
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.
An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
Even if the commissioner determines the grounds for withdrawing Avastin's accelerated approval in breast cancer have been met, she could decide to retain the claim while Genentech conducts additional confirmatory trials, the hearing notice explains.